Head-To-Head Survey: ReShape Lifesciences (OTCMKTS:RSLS) vs. Biotricity (OTCMKTS:BTCY)

ReShape Lifesciences (OTCMKTS:RSLSGet Rating) and Biotricity (OTCMKTS:BTCYGet Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.


This table compares ReShape Lifesciences and Biotricity’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ReShape Lifesciences -577.18% -72.89% -58.52%
Biotricity -265.11% -6,795.29% -155.92%

Earnings & Valuation

This table compares ReShape Lifesciences and Biotricity’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ReShape Lifesciences $13.60 million 0.31 -$61.93 million ($197.50) -0.04
Biotricity $7.70 million 4.93 -$29.13 million ($0.46) -1.59

Biotricity has lower revenue, but higher earnings than ReShape Lifesciences. Biotricity is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ReShape Lifesciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for ReShape Lifesciences and Biotricity, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ReShape Lifesciences 0 0 1 0 3.00
Biotricity 0 1 1 0 2.50

ReShape Lifesciences presently has a consensus price target of $2.88, suggesting a potential downside of 67.03%. Biotricity has a consensus price target of $4.00, suggesting a potential upside of 446.37%. Given Biotricity’s higher possible upside, analysts clearly believe Biotricity is more favorable than ReShape Lifesciences.

Institutional & Insider Ownership

3.3% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 4.8% of Biotricity shares are owned by institutional investors. 8.1% of ReShape Lifesciences shares are owned by company insiders. Comparatively, 20.5% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Biotricity beats ReShape Lifesciences on 8 of the 13 factors compared between the two stocks.

About ReShape Lifesciences

(Get Rating)

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

About Biotricity

(Get Rating)

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.